Abstract
Microorganisms present in the intestine possess proinflammatory or anti-inflammatory activities which may modulate inflammatory bowel disease (IBD). The concepts followed by researchers in trying to target the microbiota in IBD were to decrease pathogens or pathobionts, or only the microbial load, and more recently, to favor growth and persistence of favorable microorganisms. We review, here, those concepts and critically analyze the clinical data (especially randomized controlled trials) obtained using antibiotics and probiotics. We eventually present and criticize the rational and data obtained so far following new research strategies including the use of new probiotics, genetically modified organisms and fecal transplantation.
Journal Section:
Novel Therapies for IBD
References
1.
Hugot JP, Chamaillard M, Zouali H, et al: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
[PubMed]
2.
Girardin SE, Boneca IG, Viala J, et al: NOD2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003;278:8869-8872.
[PubMed]
3.
Netea MG, Kullberg BJ, De Jong DJ, et al: NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. Eur J Immunol 2004;34:2052-2059.
[PubMed]
4.
D'Haens GR, Geboes K, Peeters M, et al: Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998;114:262-267.
[PubMed]
5.
Rutgeerts P, Goboes K, Peeters M, et al: Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991;338:771-774.
[PubMed]
6.
Harper PH, Lee EC, Kettlewell MG, et al: Role of the faecal stream in the maintenance of Crohn's colitis. Gut 1985;26:279-284.
[PubMed]
7.
Sokol H, Lepage P, Seksik P, et al: Temperature gradient gel electrophoresis of fecal 16S rRNA reveals active Escherichia coli in the microbiota of patients with ulcerative colitis. J Clin Microbiol 2006;44:3172-3177.
[PubMed]
8.
Westendorf AM, Gunzer F, Deppenmeier S, et al: Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules. FEMS Immunol Med Microbiol 2005;43:373-384.
[PubMed]
9.
Ghouri YA, Richards DM, Rahimi EF, et al: Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol 2014;7:473-487.
[PubMed]
10.
Seksik P, Dray X, Sokol H, et al: Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease? Mol Nutr Food Res 2008;52:906-912.
[PubMed]
11.
Dignass A, Van Assche G, Lindsay JO, et al: The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010;4:28-62.
[PubMed]
12.
Dignass A, Lindsay JO, Sturm A, et al: Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012;6:991-1030.
[PubMed]
13.
Selby W, Pavli P, Crotty B, et al: Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 2007;132:2313-2319.
[PubMed]
14.
Steinhart AH, Feagan BG, Wong CJ, et al: Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002;123:33-40.
[PubMed]
15.
Sutherland L, Singleton J, Sessions J, et al: Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991;32:1071-1075.
[PubMed]
16.
Arnold GL, Beaves MR, Pryjdun VO, et al: Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis 2002;8:10-15.
[PubMed]
17.
Prantera C, Lochs H, Campieri M, et al: Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 2006;23:1117-1125.
[PubMed]
18.
Prantera C, Lochs H, Grimaldi M, et al: Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology 2012;142:473-481.e4.
[PubMed]
19.
Swift GL, Srivastava ED, Stone R, et al: Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease. Gut 1994;35:363-368.
[PubMed]
20.
Rutgeerts P, Hiele M, Geboes K, et al: Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-1621.
[PubMed]
21.
Rutgeerts P, Van Assche G, Vermeire S, et al: Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005;128:856-861.
[PubMed]
22.
Khan KJ, Ullman TA, Ford AC, et al: Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011;106:661-673.
[PubMed]
23.
Afdhal NH, Long A, Lennon J, et al: Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo. Dig Dis Sci 1991;36:449-453.
[PubMed]
24.
Prantera C, Kohn A, Mangiarotti R, et al: Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol 1994;89:513-518.
[PubMed]
25.
Herfarth HH, Katz JA, Hanauer SB, et al: Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2013;19:1073-1079.
[PubMed]
26.
Manosa M, Cabre E, Bernal I, et al: Addition of metronidazole to azathioprine for the prevention of postoperative recurrence of Crohn's disease: a randomized, double-blind, placebo-controlled trial. Inflamm Bowel Dis 2013;19:1889-1895.
[PubMed]
27.
Ohkusa T, Nomura T, Terai T, et al: Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. Scand J Gastroenterol 2005;40:1334-1342.
[PubMed]
28.
Ohkusa T, Kato K, Terao S, et al: Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol 2010;105:1820-1829.
[PubMed]
29.
Turunen UM, Farkkila MA, Hakala K, et al: Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 1998;115:1072-1078.
[PubMed]
30.
Burke DA, Axon AT, Clayden SA, et al: The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 1990;4:123-129.
[PubMed]
31.
Rahimi R, Nikfar S, Rezaie A, et al: A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig Dis Sci 2007;52:2920-2925.
[PubMed]
32.
Biancone L, Michetti P, Travis S, et al: European evidence-based consensus on the management of ulcerative colitis: special situations. J Crohns Colitis 2008;2:63-92.
[PubMed]
33.
Sokol H, Lay C, Seksik P, et al: Analysis of bacterial bowel communities of IBD patients: what has it revealed? Inflamm Bowel Dis 2008;14:858-867.
[PubMed]
34.
Oliva S, Di Nardo G, Ferrari F, et al: Randomised clinical trial: the effectiveness of lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther 2012;35:327-334.
[PubMed]
35.
Bourreille A, Cadiot G, Le Dreau G, et al: Saccharomyces boulardii does not prevent relapse of Crohn's disease. Clin Gastroenterol Hepatol 2013;11:982-987.
[PubMed]
36.
Malchow HA: Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997;25:653-658.
[PubMed]
37.
Guslandi M, Mezzi G, Sorghi M, et al: Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000;45:1462-1464.
[PubMed]
38.
Bousvaros A, Guandalini S, Baldassano RN, et al: A randomized, double-blind trial of lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 2005;11:833-839.
[PubMed]
39.
Marteau P, Sokol H, Dray X, et al: Bacteriotherapy for inflammatory bowel disease: therapeutic tool and/or pharmacological vectors? Gastroenterol Clin Biol 2009;33(suppl 3):S228-S234.
[PubMed]
40.
Prantera C, Scribano ML, Falasco G, et al: Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with lactobacillus GG. Gut 2002;51:405-409.
[PubMed]
41.
Marteau P, Lemann M, Seksik P, et al: Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled getaid trial. Gut 2006;55:842-847.
[PubMed]
42.
Van Gossum A, Dewit O, Louis E, et al: Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. Inflamm Bowel Dis 2007;13:135-142.
[PubMed]
43.
Tursi A, Brandimarte G, Papa A, et al: Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2010;105:2218-2227.
[PubMed]
44.
Sood A, Midha V, Makharia GK, et al: The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2009;7:1202-1209.
[PubMed]
45.
Miele E, Pascarella F, Giannetti E, et al: Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009;104:437-443.
[PubMed]
46.
Kruis W, Schutz E, Fric P, et al: Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853-858.
[PubMed]
47.
Rembacken BJ, Snelling AM, Hawkey PM, et al: Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635-639.
[PubMed]
48.
Kruis W, Fric P, Pokrotnieks J, et al: Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53:1617-1623.
[PubMed]
49.
Dignass A, Preiss JC, Aust DE, et al: [Updated German guideline on diagnosis and treatment of ulcerative colitis]. Z Gastroenterol 2011;49:1276-1341.
[PubMed]
50.
Thia KT, Mahadevan U, Feagan BG, et al: Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo controlled pilot study. Inflamm Bowel Dis 2009;15:17-24.
[PubMed]
51.
Sokol H, Pigneur B, Watterlot L, et al: Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 2008;105:16731-16736.
[PubMed]
52.
Atarashi K, Tanoue T, Shima T, et al: Induction of colonic regulatory T cells by indigenous clostridium species. Science 2011;331:337-341.
[PubMed]
53.
Furusawa Y, Obata Y, Fukuda S, et al: Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013;504:446-450.
[PubMed]
54.
Marteau P, Shanahan F: Basic aspects and pharmacology of probiotics: an overview of pharmacokinetics, mechanisms of action and side-effects. Best Pract Res Clin Gastroenterol 2003;17:725-740.
[PubMed]
55.
Steidler L, Hans W, Schotte L, et al: Treatment of murine colitis by lactococcus lactis secreting interleukin-10. Science 2000;289:1352-1355.
[PubMed]
56.
LeBlanc JG, del Carmen S, Miyoshi A, et al: Use of superoxide dismutase and catalase producing lactic acid bacteria in TNBS induced Crohn's disease in mice. J Biotechnol 2011;151:287-293.
[PubMed]
57.
Del Carmen S, de Moreno de LeBlanc A, Martin R, et al: Genetically engineered immunomodulatory Streptococcus thermophilus strains producing antioxidant enzymes exhibit enhanced anti-inflammatory activities. Appl Environ Microbiol 2014;80:869-877.
[PubMed]
58.
Motta JP, Bermudez-Humaran LG, Deraison C, et al: Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Sci Transl Med 2012;4:158ra144.
[PubMed]
59.
Hanson ML, Hixon JA, Li W, et al: Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice. Gastroenterology 2014;146:210-221.e13.
[PubMed]
60.
Antoni L, Nuding S, Wehkamp J, et al: Intestinal barrier in inflammatory bowel disease. World J Gastroenterol 2014;20:1165-1179.
[PubMed]
61.
Sarrabayrouse G, Bossard C, Chauvin JM, et al: CD4CD8αα lymphocytes, a novel human regulatory T cell subset induced by colonic bacteria and deficient in patients with inflammatory bowel disease. PLoS Biol 2014;12:e1001833.
[PubMed]
62.
van Nood E, Vrieze A, Nieuwdorp M, et al: Duodenal infusion of donor feces for recurrent clostridium difficile. N Engl J Med 2013;368:407-415.
[PubMed]
63.
Debast SB, Bauer MP, Kuijper EJ: European society of clinical microbiology and infectious diseases: update of the treatment guidance document for clostridium difficile infection. Clin Microbiol Infect 2014;2(suppl 2):1-26.
[PubMed]
64.
Colman RJ, Rubin DT: Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 2014;8:1569-1581.
[PubMed]
65.
Suskind DL, Brittnacher MJ, Wahbeh G, et al: Fecal microbial transplant effect on clinical outcomes and fecal microbiome in active Crohn's disease. Inflamm Bowel Dis 2015;21:556-563.
[PubMed]
66.
Turnbaugh PJ, Ley RE, Mahowald MA, et al: An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027-1031.
[PubMed]
67.
Marteau P: Probiotics, prebiotics, synbiotics: ecological treatment for inflammatory bowel disease? Gut 2006;55:1692-1693.
[PubMed]
68.
West RL, van der Woude CJ, Hansen BE, et al: Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2004;20:1329-1336.
[PubMed]
69.
Dewint P, Hansen BE, Verhey E, et al: Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut 2014;63:292-299.
[PubMed]
© 2015 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.